PUWEN ZHANG
No ORCID on file
· 30 papers in corpus
· active 2000-2008
Study types
- article 2
- other 1
- review 1
Condition tags
- endometriosis 4
Top journals
Frequent coauthors
- TEGLEY Christopher M. 26
- WROBEL Jay E. 26
- TEREFENKO Eugene A. 26
- JONES Todd K. 26
- SANTILLI Arthur A. 26
- VIET Andrew Q. 26
- EDWARDS James P. 26
- FENSOME Andrew 26
- GRUBB Gary S. 26
- ZHI Lin 26
other
2008
We have continued to explore the 3,3-dialkyl-5-aryloxindole series of progesterone receptor (PR) modulators looking for new agents to be used in female healthcare: contraception, fibroids, endometriosis, and certain breast cancers. Previous…
review
2005
Progesterone, acting primarily via the progesterone receptor (PR), plays an essential role in the regulation of female reproduction. Steroidal progestins (i.e., PR agonists) are commonly used in women's health, such as in contraception and …
article
2003
Progesterone (P4) plays an essential role in female reproduction and progesterone receptor (PR) agonists have been used in female contraceptives and in postmenopausal hormone therapy. Recent studies in women and non-human primates show that…
article
2003
Progesterone (P4) plays an essential role in female reproduction and progesterone receptor (PR) agonists have been used in female contraceptives and in postmenopausal hormone therapy. Recent studies in women and non-human primates show that…
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2002
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R1 and R2 are H, CORA, NRBCORA, …
2000
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R and R are H, COR, NRCOR, or op…
2000
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R and R are H, COR, NRCOR, or op…
2000
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R and R are H, COR, NRCOR, or op…
2000
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R and R are H, COR, NRCOR, or op…
2000
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R and R are H, COR, NRCOR, or op…
2000
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R and R are H, COR, NRCOR, or op…
2000
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R and R are H, COR, NRCOR, or op…
2000
This invention concerns cyclic combination therapies using indoline derivatives which are progesterone receptor antagonists of general structure (I) wherein: A, B and D are N or CH, though not all can be CH; R and R are H, COR, NRCOR, or op…